comparemela.com

Latest Breaking News On - Gamaleya national research centre - Page 8 : comparemela.com

How safe is Russia s Sputnik V vaccine and how does it differ from Oxford/AstraZeneca s Covid vaccine

91 6% Efficacy, Rare Adverse Effects: All You Need to Know About Russia s Sputnik V Vaccine

91.6% Efficacy, Rare Adverse Effects: All You Need to Know About Russia s Sputnik V Vaccine News18 1 hour ago News18 Russia’s COVID-19 vaccine Sputnik V on Monday received approval of Centre’s expert panel for emergency use in India with certain conditions. The Drugs Controller General of India (DCGI) will take a final call on the recommendation of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO), which took up the application of Dr Reddy’s Laboratories seeking emergency use authorisation for Sputnik V. © Provided by News18 91.6% Efficacy, Rare Adverse Effects: All You Need to Know About Russia s Sputnik V Vaccine

Ground News - Russia s Sputnik V vaccine 97 6% effective in real-world study

Russia s Sputnik V vaccine 97.6% effective in real-world studyRussian scientists have found the Sputnik V vaccine 97.6% effective against COVID-19 in a real-world assessment based on data from 3.8 million people, Moscow s Gamaleya Institute and the Russian Direct Investment Fund said on Monday. The new effectiveness rate is higher than the 91.6% rate outlined in results from a large-scale trial of Sputnik V that was published in The Lancet medical journal earlier this year, and compar 8 days ago|Moscow, Russian Federation BIAS DISTRIBUTION 4 lean

New York raises indoor venue capacity; South Africa reg

New York raises indoor venue capacity; South Africa reg
dailymaverick.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymaverick.co.za Daily Mail and Mail on Sunday newspapers.

Russia s Sputnik V vaccine 97 6% effective in real-world study: Scientist

MOSCOW (BLOOMBERG, REUTERS) - An analysis of the 3.8 million Russians who received both Sputnik V shots between December and March showed that the vaccine has 97.6 per cent efficacy, the inoculation s state-run developers said in a statement on Monday (April 19). The data, which compare the infection rate of people who received the shots with the incidence among the unvaccinated population, will be published in a peer-reviewed journal in May, according to the Russian Direct Investment Fund and Gamaleya National Research Centre. The new effectiveness rate is higher than the 91.6 per cent rate outlined in results from a large-scale trial of Sputnik V and published in The Lancet medical journal earlier this year.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.